Abbott Laboratories $ABT Stock Holdings Decreased by Gradient Investments LLC

Gradient Investments LLC lessened its position in Abbott Laboratories (NYSE:ABT) by 24.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 178,998 shares of the healthcare product maker’s stock after selling 57,265 shares during the quarter. Gradient Investments LLC’s holdings in Abbott Laboratories were worth $17,690,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Juncture Wealth Strategies LLC bought a new stake in Abbott Laboratories in the 3rd quarter valued at $658,000. Aureus Asset Management LLC lifted its stake in Abbott Laboratories by 25.0% during the first quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock worth $34,078,000 after purchasing an additional 66,422 shares during the period. Thompson Investment Management Inc. grew its stake in shares of Abbott Laboratories by 786.0% in the 2nd quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker’s stock valued at $1,276,000 after purchasing an additional 12,474 shares during the period. Parnassus Investments LLC raised its holdings in shares of Abbott Laboratories by 17.5% in the 4th quarter. Parnassus Investments LLC now owns 616,351 shares of the healthcare product maker’s stock worth $77,223,000 after buying an additional 91,897 shares in the last quarter. Finally, Clear Harbor Asset Management LLC acquired a new stake in Abbott Laboratories in the 2nd quarter valued at $4,889,000. 75.18% of the stock is owned by institutional investors and hedge funds.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays initiated coverage of Abbott Laboratories with an Overweight rating and a $120 price target, implying approximately 23% upside from the recently quoted share price. The bullish view supports ABT by pointing to potential value at current levels. Abbott Laboratories Now Covered by Analysts at Barclays
• Positive Sentiment: Barclays also listed Abbott among its overweight medtech ideas as it turned more constructive on the sector. Additional positive analyst sentiment could help offset recent selling pressure. Stryker, Abbott among overweight ideas as Barclays turns bullish on MedTech
• Positive Sentiment: The FDA approved updates to Abbott’s CardioMEMS heart-failure system, adding smartphone-based pulmonary-pressure readings and clinician-guided treatment adjustments. The CardioGuide HF App and Dynamic Treatment Plan strengthen Abbott’s connected cardiac-care offering and could support future adoption. FDA-Approved CardioMEMS App Integration
• Positive Sentiment: Abbott partnered exclusively with Berry Street to connect its over-the-counter Lingo glucose biosensor with insurance-supported nutrition coaching. The arrangement expands potential use cases for Abbott’s diabetes and metabolic-health technology. Abbott Ties Glucose Tracking to Live Nutrition Coaching
• Neutral Sentiment: Abbott introduced Ensure Max Protein 3-in-1 Muscle Support, combining protein, creatine, and HMB in one serving. The launch broadens Abbott’s consumer-health portfolio, although its near-term financial impact is unclear. Abbott Introduces Ensure Max Protein 3-in-1 Muscle Support
• Neutral Sentiment: Investor interest in ABT remains elevated, while its record of 411 consecutive quarterly dividend payments continues to appeal to income-focused investors. These factors may provide support but do not directly change earnings expectations. Is Abbott Laboratories a Dividend Bargain After Its 2026 Selloff?
• Negative Sentiment: Despite the bullish analyst commentary, ABT has remained under pressure after a difficult 2026 performance. Commentary that Abbott is not showing rapid growth, combined with a relatively elevated earnings multiple, may be limiting investor enthusiasm. Abbott Stock Drops Despite Market Gains

Abbott Laboratories Price Performance

NYSE:ABT traded down $0.45 during mid-day trading on Thursday, reaching $98.28. 3,090,664 shares of the company were exchanged, compared to its average volume of 11,302,686. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The stock has a market cap of $170.06 billion, a PE ratio of 31.85, a PEG ratio of 1.82 and a beta of 0.59. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $135.13. The company has a fifty day moving average of $106.52 and a 200 day moving average of $98.39.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same period in the prior year, the business earned $1.26 earnings per share. Abbott Laboratories’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.6%. Abbott Laboratories’s payout ratio is presently 81.55%.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Rothschild & Co Redburn upgraded Abbott Laboratories from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $119.00 to $127.00 in a research note on Friday, October 2nd. Royal Bank Of Canada reiterated an “outperform” rating and set a $130.00 target price on shares of Abbott Laboratories in a research report on Friday, July 17th. Piper Sandler restated an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a report on Thursday, August 13th. Finally, Bank of America reduced their target price on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.88.

About Abbott Laboratories

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.